Company profile: Spectrum Antimicrobials
1.1 - Company Overview
Company description
- Provider of pharmaceutical drug development specializing in antibiotics and therapeutics.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Spectrum Antimicrobials
Bluejay Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical drug candidates for infectious diseases, including BJT-778, a fully human IgG1 monoclonal antibody designed to neutralize and facilitate clearance of HDV virions, contributing to a potential functional cure for CHB/CHD, and BJT-628, an oral liver-targeted HBV transcript inhibitor reducing HBsAg. Offers the Bluejay L-TAP platform for liver-targeted oral delivery and runs Phase 1/2a trials in chronic hepatitis B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluejay Therapeutics company profile →
Venatorx Pharmaceuticals
HQ: United States
Website
- Description: Provider of anti-infective therapies for multi-drug-resistant bacterial and viral infections, including cefepime-taniborbactam for complicated urinary tract infections and potentially hospital-acquired and ventilator-associated bacterial pneumonia; ceftibuten-ledaborbactam etzadroxil for drug-resistant Enterobacterales; and a PBP inhibitor program developing non-beta-lactam molecules.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Venatorx Pharmaceuticals company profile →
Iterum Therapeutics
HQ: Ireland
Website
- Description: Provider of clinical-stage anti-infectives targeting multi-drug resistant pathogens. Offers sulopenem, an oral and IV penem antibiotic with broad-spectrum activity against multi-drug resistant gram-negative infections in hospital and community settings.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iterum Therapeutics company profile →
Lumos Diagnostics
HQ: United States
Website
- Description: Provider of rapid point-of-care diagnostic solutions, including customized assay development, full-scale contract manufacturing for lateral flow strips and readers, proprietary digital reader platforms, companion apps, and cloud connectivity for data capture and visualization, supported by in-house clinical study design, site management, and regulatory affairs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Lumos Diagnostics company profile →
Arbutus Biopharma
HQ: Canada
Website
- Description: Provider of biopharmaceutical therapies for hepatitis B virus (HBV), including Imdusiran (AB-729), a subcutaneously delivered RNAi therapeutic designed to reduce HBV viral antigens such as HBsAg, and AB-101, an oral PD-L1 inhibitor intended to reawaken HBV-specific T cells by blocking the PD-1/PD-L1 protein-protein interaction.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arbutus Biopharma company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Spectrum Antimicrobials
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Spectrum Antimicrobials
2.2 - Growth funds investing in similar companies to Spectrum Antimicrobials
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Spectrum Antimicrobials
4.2 - Public trading comparable groups for Spectrum Antimicrobials
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →